Heterotricyclic compounds as CRF receptor antagonists

(19)

(11)

EP 1 832 590 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.04.2012 Bulletin 2012/17

(45)	Mention of the grant of the patent:
	28.09.2011 Bulletin 2011/39

(21)	Application number: 07111569.5

(22)	Date of filing: 27.12.2001

(51)

International Patent Classification (IPC):

C07D 487/04^(2006.01)
A61P 3/00^(2006.01)
A61P 9/00^(2006.01)
C07D 491/14^(2006.01)
A61K 31/435^(2006.01)

A61P 1/00^(2006.01)
A61P 5/00^(2006.01)
C07D 471/04^(2006.01)
C07D 495/14^(2006.01)
A61K 31/495^(2006.01)

(54)	Heterotricyclic compounds as CRF receptor antagonists Heterotrizyklische Verbindungen als Antagonisten des CRF-Rezeptors Composés tri-hétérocycliques comme inhibiteurs du recépteur CRF

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30)

Priority:

28.12.2000 JP 2000402517

(43)	Date of publication of application:
	12.09.2007 Bulletin 2007/37

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	01995808.1 / 1354884

(73)	Proprietor: ONO PHARMACEUTICAL CO., LTD.
	Osaka-shi, Osaka 541-8526 (JP)

(72)	Inventors:
	Nakai, Hisao Ono Pharmaceutical Co., Ltd. Osaka 618-8585 (JP) Kagamiishi, Yoshifumi Ono Pharmaceutical Co., Ltd. Osaka 618-8585 (JP)

(74)	Representative: Grünecker, Kinkeldey, Stockmair & Schwanhäusser
	Anwaltssozietät Leopoldstrasse 4 80802 München 80802 München (DE)

(56)

References cited: :

WO-A-00/27846
WO-A-99/64422

WO-A-00/27850

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).